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RESUMEN
Objetivos: El objetivo principal del presente estudio es el de facilitar la administración intranasal 
de tartrato de metoprolol (cardioselectivo β1-bloqueante), mediante la formulación de microesferas 
mucoadhesivas.  
Métodos: Las microesferas se preparan por precipitación iónica y el método químico de reticulación. 
Las microesferas se caracterizaron mediante determinación del tamaño de partícula, morfología 
de la superficie, la eficiencia de atrapamiento, estudio in vitro de la liberación del fármaco y por 
espectroscopia infrarroja. 
Resultados: El tamaño de partícula y retención máxima de formulación optimizada (MT 4) fue de 
1897 nm y  94,19± 0,015%, respectivamente. La liberación del fármaco in vitro en una solución salina de 
tampón fosfato (pH=7,4) fue 97,88 ± 0,02% en la formulación de MF1.  La tasa de liberación del fármaco 
puede ser adaptada mediante la manipulación del grado de cristalinidad, la menor cristalinidad 
favorece una liberación mas lenta. El fármaco empleado puede inducir la escisión de la cadena de 
polímeros a través de la degradación del nucleófilo. Los resultados de los análisis de infrarrojos no 
moistraron ningún tipo de alteración producida por el proceso de microencapsulación 
Conclusiones: el tartrato de metoprolol liberado en la mucosa nasal es aceptable para conseguir 
reducir los niveles elevados de presión arterial.
PALABRAS CLAVE: Tartrato de metoprolol, Microesferas de quitosano, Microfotografía.
ABSTRACT 
Aim: The main objective of present study was to facilitate intranasal delivery of Metoprolol tartrate 
(cardioselective β1-blocker) by formulating mucoadhesive microspheres. 
Methods: The microspheres were prepared by ionic precipitation and chemical cross-linking method. 
Microsphere formulations were characterized for particle size, surface morphology, entrapment 
efficiency, in vitro drug release and Infrared Spectroscopy. 
Results: The particle size and maximum entrapment of optimized formulation (MT 4) was found 
to be 1897 nm, 94.19±0.015 %, respectively.  In vitro drug release in phosphate buffer saline (pH 
7.4) was maximum (97.88±0.02 %) in formulation MF1. The drug release rate can be tailored by 
manipulating the degree of crystallinity, reduced crystallinity is favorable when slow release is 
desired. The drug employed can induce polymer chain scission through nucleophilic degradation. 
The results of the infrared analysis were in agreement with reference as no new chemical species 
after the microencapsulation process was observed. 
Conclusions: To conclude, the drug (metoprolol tartrate) thus released in nasal mucosa will attain 
therapeutic plasma concentration and reduce elevated blood pressure levels. 
 KEY WORDS: Metoprolol tartrate, Chitosan Microspheres, Microphotograph.
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INTRODUCTION
The WHO has estimated that high blood pressure causes 
one in every eight deaths, making hypertension the third 
leading killer in the world. Globally, there are one billion 
hypertensives and four million people die annually as a 
direct result of hypertension. By 2010, 1.2 billion people will 
be suffering hypertension worldwide.1 Metoprolol tartrate 
is a Beta-adrenoreceptor blocking (antihypertensive) 
agent. It is the prototype of cardioselective (β1) blockers, its 
potency to block cardiac stimulation.2
Nasal drug delivery system has been practiced since very 
old times for systemic effects. In modern pharmaceutics, 
the nose had been considered primarily as a route for 
local drug delivery. The last 2 decades have witnessed a 
number of advances in pharmaceutical biotechnology 
resulting in possibilities for large scale production of 
biopharmaceuticals especially proteins and peptides. The 
inability to administer these drugs by routes other than 
parenteral route motivated scientists to explore other 
possibilities such as pulmonary and nasal administrations. 
On the other hand very good results were obtained with 
small organic molecules which led to the successful 
development of a number of products currently in the 
market.3 Examination of the causes of failure led to the 
conclusion that the short residence time of the formulation 
within the nasal cavity coupled to the low permeability of the 
later did play significant role. Consequently, the attention 
shifted to the evaluation of mucoadhesive polymers, some 
of which would even demonstrate additional permeation 
enhancing capabilities. The encouraging results and the 
desire to overcome some new challenges stimulated the 
development of new generations of polymers based on pH 
or thermal responsiveness,4,5 or modified existing polymers 
having improved bioadhesive or permeation enhancing 
properties.6-8 Even though a number of challenges are still 
to be overcome, especially with respect to toxicity, the 
potential of nasal drug delivery, including the ability to 
target drugs across the blood brain barrier (BBB), are very 
high and continues to provoke academics and industries. 
Due to their short residence of the time at the absorption 
site, the success of microspheres as drug delivery systems 
is narrow. The main advantage of this system is it provides 
an close contact with the absorbing membranes. It can 
be achieved by imparting bioadhesion characteristics to 
microspheres and developing novel delivery systems 
referred to as “bioadhesive microspheres”. Bioadhesive 
microspheres system includes microcapsules and 
microparticles of 1-1000 nm in diameter and consist of 
bioadhesive polymer or as an outer coating materials of it, 
respectively.9 The polymers such as hydroxypropylcellulose 
(HPC),10,11 chitosan,12-14 carbopol,15 carboxy-methylcellulose, 
hyaluronic acid and polyacrylic acid have all shown 
promise as muco/bio-adhesive agents for potential use in 
pulmonary delivery,16 either alone, in combination with 
another carrier or incorporated into the structure of the 
carrier itself.17
The present work was carried out with the goal to 
deliver metoprolol tartrate via nasal route by formulating 
mucoadhesive particulates (microspheres) of chitosan. The 
influence of various process variables was observed on the 
particle size, entrapment efficiency (EE) and in vitro drug 
release of microsphere formulations.
MATERIALS AND METHODS
Materials
The drug metoprolol tartrate was procured as a gift 
sample from Torrent Pharmaceuticals, Aurangabad, 
India. Chitosan (Mw. 5 x105-1x106, 80% deacetylated) 
was provided at gratis from Central Institute of Fisheries 
Technology, Kochi, India. The Acetic acid, Sodium 
Sulphate and Glutaraldehyde were purchased from CDH 
Limited, New Delhi, India. The Tween 80 was purchased 
from Himedia Labs, Mumbai, India. All chemicals were of 
analytical grade.
Methods
Preparation of Microspheres
The microsphere system was prepared by ionic precipitation 
and chemical cross linking method. A specific amount of 
chitosan was dissolved in 100 ml of acetic acid solution 
(2% v/v). To the above solution Tween-80 (1% v/v) was 
added with constant stirring. Then sodium sulphate (20% 
w/v) solution was added during the stirring process, 
drop wise, until uniform turbidity was achieved. To this, 
glutaraldehyde (1% w/v) was added as cross linking 
agent and solution was homogenized for additional 
1hr to stabilize the microspheres. Then microsphere 
suspension was centrifuged at 3000 x g (GPR Centrifuge, 
Beckman Instruments, Palo Alto, CA, USA) for 15 min and 
microspheres were collected. The microspheres were washed 
twice with distilled water and freeze-dried. The drug was 
then adsorbed on the surface of so formed microspheres. 
The microspheres were suspended in distilled water and 
drug was added to this aqueous dispersion in micro test 
tubes at 20 °C with vigorous shaking at every 15 min. The 
pH of the loading medium was maintained at 4.0±0.2 with 
acetic acid. After 3 h, the samples were centrifuged for 30 
min (Capsule HF-120, Tomy Seiko Co. Ltd, Tokyo, Japan) 
and the supernatant was measured spectrophotometrically 
after dilution with water.18
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Figure 1. Microphotograph of metoprolol tartrate 
loaded microspheres
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Characterization of chitosan microspheres
Particle Size Distribution and Surface Charge (Zeta 
Potential)
Metoprolol tartrate loaded microspheres were suspended 
in distilled water for size distribution analysis with the 
help of Malvern Zeta sizer (Malvern ZS-90 instrument Ltd 
U.K.).18
Surface Morphology
The morphology of the microspheres was determined by 
observation on a fluorescent microscope. The samples were 
prepared in distilled water and mounted on glass slide to 
determine the morphology of microspheres with the help 
of Fluorescent microscope (Radical Rx Lr 3T).18
Entrapment Efficiency (EE)
The entrapment efficiency of microspheres prepared by 
ionic precipitation technique was determined by using 
cooling centrifuge. The microsphere dispersions were 
centrifuged at 3000 × g for 30 min in acetic acid solution. 
The clear supernatant was analyzed for metoprolol tartrate 
by UV-spectrophotometeric method at 274 nm. The drug-
loading efficiency was determined as the ratio between 
the analytical and theoretical drug content.19 All the 
experiments were performed in triplicate. It was calculated 
using following formula:
%EE =                                                                              x 100
Amount of metroprolol tartrate entrapped
Total of metroprolol tartrate
Infrared Spectroscopy 
Infrared spectroscopy of the drug-loaded microspheres 
was performed at ambient temperature in the range of 
400-4000cm-1, using potassium bromide pellets in FT-IR 
spectrometer (JASCO, Japan).20
In Vitro Drug Release
The chitosan microspheres were suspended in small 
volume of phosphate buffer saline (pH 7.4) in order to 
determine drug release behavior. This suspension was 
placed in an egg membrane and suspended in beaker filled 
with 50 ml of dissolution medium. This solution was stirred 
at 100 rpm with magnetic stirrer at 37±1°C. Sink conditions 
were maintained during the drug dissolution study.19 
Sampling was done at specific intervals. At each sampling, 
3 ml of the solution was withdrawn and replenished with 
fresh medium. The drug concentration was measured at 
respective λmax in respective medium using UV/visible 
spectrophotometer (Shimadzu 1700, Japan).
RESULTS AND DISCUSSION
Preparation of Metoprolol Tartrate Loaded Chitosan 
Microspheres
Precipitation and precipitation chemical cross-linking 
methods are rapid and simple techniques for producing 
metoprolol tartrate loaded microspheres with small size 
and good reproducibility.  This production process is based 
on the solubility behavior of Chitosan, which is sparingly 
soluble in water. Addition of an acid improves its solubility 
as a result of protonation of amino groups. Chitosan 
solubility is also affected by other anions present in the 
solution. In the presence of phosphate, polyphosphate and 
sulphate ions, Chitosan shows a decreased solubility18. For 
this reason, sodium sulphate was chosen for microsphere 
formulations, since sulphate leads to a poorly soluble 
Chitosan derivative, facilitating microsphere formulation 
possible. 
Particles Size and Surface Morphology
The chitosan microspheres were spherical and particle 
size of optimized formulation (MT 4) was found to be 
1897 nm. The change in particle size was observed upon 
varying processing variables as concentration of chitosan 
and stirring speed. It was concluded that on decreasing 
the concentration of polymer and on increasing the stirring 
rate the size of microspheres was decreased. The cross-
linked microspheres were smaller than the corresponding 
uncross-linked particles in compliance with expectation. 
These differences in size indicate that cross linked 
microspheres were more compact in structure because of 
the cross-linkage. Optical micrographs showed spherical 
particles (Figure 1).
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Table 1. Effect of various processing parameters on entrapment efficiency (EE) of microspheres.
Investigation of the Zeta potential is an important part 
of microsphere characterization. The phosphate buffer 
influenced measurement of Zeta potential, due to the effect 
of the counter ions on the positively charged chitosan 
microspheres. Chitosan microspheres were positively 
charged (Zeta Potential 5.59 mV-Formulation MT4), 
although sulphate ions were used as precipitant. This 
was concluded that only a part of the amino groups are 
neutralized during microsphere formation. 
Entrapment Efficiency
The entrapment efficiency of metoprolol loaded 
microspheres was performed as per reported method 
in order to estimate the actual amount of drug being 
entrapped in microspheres. Encapsulation efficiency was 
estimated after freeze-drying. On the basis of entrapment 
efficiency the acetic acid concentration, drug polymer ratio, 
stirring speed, glutaraldehyde concentration, and tween 80 
concentrations were optimized. 
In chitosan microspheres formulation, the increase in 
stirring rate will disperse the precipitating agent in solution 
rapidly and also due to increase in shearing force, the size 
Formulation 
Code
Concentration (%)
Drug:polymer 
ratio
Stirring 
rate (r/m)
Entrapment 
efficiency (%)Glutaraldehyde Acetic acid Tween80
MA 1 1.0 57.89±0.36
MA 2 1.5 69.41±0.54
MA 3 2.0 77.28±0.42
MA 4 2.5 73.65±0.46
MDP 1 1:0.5 47.47±0.89
MDP 2 1: 1.0 71.83±1.37
MDP 3 1: 1.5 78.29±0.53
MDP 4 1: 2.0 64.84±0.37
MT 1 0.8 74.87±0.14
MT 2 1.0 81.01±0.04
MT 3 1.2 86.71±0.84
MT 4 1.4 94.19±0.015
MD 1 0.8 66.05±0.18
MD2 1.0 77.29±0.42
MD 3 1.2 80.37±0.16
MD4 1.4 75.05±0.18
MS 1 2000 63.24±0.14
MS2 2500 70.14±0.17
MS 3 3000 77.28±0.43
MS4 3500 80.74±0.26
of microspheres decreases and the % drug entrapment 
increases. It was observed that entrapment efficiency 
increases with increase in surfactant concentration. The 
metoprolol tartrate loaded microspheres were produced 
by the ionic precipitation technique using different 
concentrations of cross linking agent (glutaraldehyde). 
Glutaraldehyde is probably able to interact with the amine 
groups of metoprolol tartrate, forming a complex that 
forms the microspheres. On increasing concentration of 
glutaraldehyde the amount of free drug was decreased 
(Table1).
In Vitro Drug Release
In vitro drug release from microspheres was performed in 
phosphate buffer saline (pH 7.4) through egg membrane. 
The natural membranes (such as egg membrane, peach and 
tomato skin, inter-lamellar layer of the onion) used, have 
pores and channels with hydrophilic properties which 
permeates small to middles size hydrophilic drugs to 
diffuse in a manner similar to human skin, and because of its 
availability can be used for in vitro diffusion studies. It was 
reported that on increasing the concentration of polymer 
Ars Pharm. 2012; 53(3): 13-18.
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the release rate of drug from chitosan microspheres were 
decreased, as the thickness of polymer was increased and 
diffusion distance for drug to diffuse out from microspheres 
was increased. The observations were made continuously 
for 18 hr. The release profiles were also dependent on the 
size of the microspheres, the rate of drug release was found 
to decrease with increasing particle size of microspheres. 
This may be useful for the controlled release of a drug 
inside the core matrix since the release rate is controlled by 
diffusion through a shell of uniform thickness. The results 
of in vitro drug release studies are showed in Figure 2, 
Figure 3 and Figure 4.
Infrared Spectroscopy 
It was performed on metoprolol tartrate loaded chitosan 
microspheres to identify the drug polymer interactions. 
The characteristic IR spectra were very similar, showing all 
the bands of the functional groups of drug in metoprolol 
tartrate loaded microspheres. The results of the IR analysis 
were in an agreement for which no new chemical species 
after the microencapsulating process was observed 
but there are slight shift in peaks that is due to physical 
interaction as 841 nm instead of  822 nm, 1126 nm instead 
of 1111 nm, 1024 nm instead of 1023 nm.
CONCLUSION
The present research work was an attempt to overcome 
pitfalls associated with conventional drug delivery systems 
such as fluctuation in plasma drug concentration, lack of 
target specificity. The chitosan (biocompatible polymer) 
microspheres of metoprolol tartrate delivered via nasal 
route ensure high degree of absorption and rapid transport 
of absorbed substances into the systemic circulation for 
initiation of therapeutic action. 
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